EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Efficacy and Safety of Sorafenib or Lenvatinib for Advanced Hepatocellular Carcinoma after Failure of First-Line Atezolizumab Plus Bevacizumab: A Systematic Review and Meta-Analysis

Tzu-Rong Peng iD, Yi-Fang Weng, Ta-Wei Wu, Chao-Chuan Wu, Yi-Chun Chou, Ching-Sheng Hsu iD

Cancers · 10.08.2024 · 16 (16) · 2813

DOI: 10.3390/cancers16162813 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 10.08.2024. Verfasst von Tzu-Rong Peng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City 231, Taiwan. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Although atezolizumab plus bevacizumab (hereinafter, atezolizumab–bevacizumab) is the standard first-line treatment for patients with advanced HCC, the optimal second-line regimen remains unknown. This study evaluated the efficacy and safety of sorafenib and lenvatinib in patients with advanced HCC that progressed under atezolizumab–bevacizumab treatment.

Methods

Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, we searched PubMed, Embase, and the Cochrane Library for articles published before November 2023. Random-effects meta-analysis was performed to determine the pooled objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS), comparing patients who received sorafenib versus lenvatinib.

Results

Seven studies involving 387 patients were included. The pooled ORR, DCR, OS, and PFS for sorafenib and lenvatinib together were 26% (95% CI: 14–43%), 63% (95% CI: 47–77%), 11.45 months (95% CI: 7.12–15.77, I2 = 92%, p < 0.01), and 3.78 months (95% CI: 2.34–5.23, I2 = 67%, p = 0.02), respectively. Although lenvatinib users had a longer median OS (12.42 vs. 10.75 months) and PFS (5.15 vs. 2.58 months) than sorafenib users, the pooled ORR, DCR, median OS, and PFS for these medications were comparable. Additionally, the distributions of all-grade and grade ≥ 3 adverse events for sorafenib and lenvatinib were comparable to those for these two medications when used as first-line therapies.

Conclusions

Sorafenib or lenvatinib can provide effective treatment with manageable toxicity in patients with advanced HCC after disease progression under atezolizumab–bevacizumab.

Schlagwörter

Stichwörter der Autor:innen

hepatocellular carcinomalenvatinibmeta-analysissequential therapysorafenib

Autor:innen und Institutionen

  • Department of Pharmacy, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City 231, Taiwan.
  • Department of Surgery, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City 231, Taiwan.
  • School of Medicine, Tzu Chi University, Hualien 97004, Taiwan.
  • Division of Gastroenterology, Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chia-Yi 62247, Taiwan.
  • Liver Diseases Prevention and Treatment Center, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chia-Yi 62247, Taiwan.
  • School of Post-Baccalaureate Chinese Medicine, Tzu Chi University, Hualien 97004, Taiwan.

ORCID-Profile: Tzu-Rong Peng, Ching-Sheng Hsu

Förderung

  • Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation

Zitieren

APA

Peng, T. R., Weng, Y. F., Wu, T. W., Wu, C. C., Chou, Y. C., & Hsu, C. S. (2024). Efficacy and Safety of Sorafenib or Lenvatinib for Advanced Hepatocellular Carcinoma after Failure of First-Line Atezolizumab Plus Bevacizumab: A Systematic Review and Meta-Analysis. Cancers, 16(16), 2813. https://doi.org/10.3390/cancers16162813

Vancouver

Peng TR, Weng YF, Wu TW, Wu CC, Chou YC, Hsu CS. Efficacy and Safety of Sorafenib or Lenvatinib for Advanced Hepatocellular Carcinoma after Failure of First-Line Atezolizumab Plus Bevacizumab: A Systematic Review and Meta-Analysis. Cancers. 2024;16(16):2813. doi:10.3390/cancers16162813

BibTeX
@article{Peng2024,
  author = {Peng, Tzu-Rong and Weng, Yi-Fang and Wu, Ta-Wei and Wu, Chao-Chuan and Chou, Yi-Chun and Hsu, Ching-Sheng},
  title = {Efficacy and Safety of Sorafenib or Lenvatinib for Advanced Hepatocellular Carcinoma after Failure of First-Line Atezolizumab Plus Bevacizumab: A Systematic Review and Meta-Analysis},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {16},
  pages = {2813},
  doi = {10.3390/cancers16162813}
}
Kostenlos starten →